IMMX Reports 89% CR in NXC-201; IRC Confirmation Still Missing

What happened

Immix Biopharma announced updated NXC-201 data showing an 89% complete response rate in relapsed/refractory AL amyloidosis, along with plans for a BLA, a frontline study, and a targeted commercial launch. This follows the June 2026 master report that flagged a 20-percentage-point gap between the SEC-filed 75% IRC-confirmed CR and the company-presented 95% CR, and called for the late-September update to reconcile these figures. The new 89% figure sits between the two prior rates, but the news article does not specify whether it is IRC-confirmed, the denominator used, or the data cutoff, leaving the core discrepancy only partially addressed. The accompanying regulatory and commercial announcements signal management confidence, but they are contingent on a robust confirmatory dataset that has yet to be demonstrated. Until the company provides SEC-filed clarity on the 89% CR's adjudication and the trial denominator, the update should be treated as preliminary and inconclusive.

Implication

The updated 89% CR rate will only be meaningful if it is independently confirmed and applies to a clearly defined evaluable population; otherwise, the prior discrepancy between 75% IRC and 95% investigator rates may persist in some form. The announced BLA and frontline study plans are contingent on the full dataset meeting regulatory standards, and the commercial strategy remains speculative without an approved product. Given the open $100M ATM and the company's ongoing cash burn, investors should be wary of chasing this news until detailed SEC filings provide the necessary data reconciliation. If subsequent filings confirm an IRC-adjudicated CR rate near or above 90% on a denominator consistent with the company's prior guidance (n=40 or 45), the stock could re-rate upward; however, if the rate is lower or denominator issues remain, downside is significant. We maintain our WAIT rating and recommend waiting for the next 10-Q/8-K filing that should contain the audited clinical data before making any investment decision.

Thesis delta

The new 89% CR update reduces the magnitude of the previously identified discrepancy but does not eliminate it, as the report lacks IRC confirmation and denominator clarity. Our WAIT thesis is unchanged; the key trigger for upgrade remains a SEC-filed dataset showing IRC-confirmed CR ≥90% on a clearly defined denominator, while a downgrade would occur if the rate falls below 75% or denominator ambiguity persists. The addition of BLA and frontline plans is neutral to the thesis until regulatory-grade data are presented.